Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Minority Interest (2021 - 2025)

Bioventus (BVS) has disclosed Minority Interest for 5 consecutive years, with $44.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Minority Interest rose 17.73% year-over-year to $44.3 million, compared with a TTM value of $44.3 million through Dec 2025, up 17.73%, and an annual FY2025 reading of $44.3 million, up 17.73% over the prior year.
  • Minority Interest was $44.3 million for Q4 2025 at Bioventus, up from $41.2 million in the prior quarter.
  • Across five years, Minority Interest topped out at $140.7 million in Q4 2021 and bottomed at $35.7 million in Q4 2022.
  • Average Minority Interest over 5 years is $55.9 million, with a median of $46.8 million recorded in 2023.
  • Peak annual rise in Minority Interest hit 36.86% in 2023, while the deepest fall reached 45.36% in 2023.
  • Year by year, Minority Interest stood at $140.7 million in 2021, then tumbled by 38.17% to $87.0 million in 2022, then crashed by 45.36% to $47.5 million in 2023, then decreased by 20.75% to $37.7 million in 2024, then grew by 17.73% to $44.3 million in 2025.
  • Business Quant data shows Minority Interest for BVS at $44.3 million in Q4 2025, $41.2 million in Q3 2025, and $40.1 million in Q2 2025.